Evidence map›Paper›PMID 39449335›Full record

ArticleCurrent medicinal chemistry2026

Design, Synthesis, Molecular Docking, Pharmacokinetic Properties, and Molecular Dynamics Simulation of Sulfonyl Derivatives of Benzimidazole against Parkinson's Disease.

Subarna Roy, Subhankar Basak, Shristi Roy, Paromita Dey, Hema Barman, Bhagat Singh, Kaushik Sarkar, Subhadeep Sen, Rajesh Kumar Das, Sudhan Debnath and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Subarna RoyDepartment of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal, 736101, India.
Subhankar BasakDepartment of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal, 736101, India.
Shristi RoyDepartment of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal, 736101, India.
Paromita DeyDepartment of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal, 736101, India.
Hema BarmanDepartment of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal, 736101, India.
Bhagat SinghDepartment of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina 27402, United States.
Kaushik SarkarDepartment of Chemistry, University of North Bengal, Darjeeling, West Bengal, 734013, India.
Subhadeep SenDepartment of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal, 736101, India.
Rajesh Kumar DasDepartment of Chemistry, University of North Bengal, Darjeeling, West Bengal, 734013, India.
Sudhan DebnathDepartment of Chemistry, Netaji Subhash Mahavidyalaya, Udaipur, Tripura, 799114, India.
Goutam BiswasDepartment of Chemistry, Cooch Behar Panchanan Barma University, Cooch Behar, West Bengal, 736101, India.ORCID 0000-0002-1488-2003

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe disability and mortality related to Parkinson's disease (PD), a neurodegenerative disease, are increasing globally at a faster rate than other neurological disorders. With no permanent cure for PD, there is an urgent need to develop novel and effective anti-PD drugs.

methodsTargeting monoamine oxidases (MAO), which catalyze the breakdown of neurotransmitters, is one way to treat neurodegenerative diseases. In this context, an initial molecular docking of twenty designed sulfonyl derivatives of benzimidazole against monoamine oxidase B (MAO-B) associated with PD was conducted using AutoDock Vina.

resultsThe results were compared with those of the conventional inhibitors, selegiline and rasagiline. Based on the docking score, the in silico pharmacokinetic properties (ADME), drug-likeness, and toxicity profiles of the newly synthesized molecules were examined using SwissADME, PreADMET, ProTox-3.0, vNN, and ADMETlab web tools. Then, twelve potential derivatives were synthesized and characterized by IR,

conclusionThis study indicates that the binding affinity of most of the hits was superior to that of known MAO inhibitors; therefore, these newly synthesized benzimidazole derivatives may be developed into essential drug candidates for the treatment of PD.

Indexed as

BenzimidazolesDrug DesignMolecular Docking SimulationMolecular Dynamics SimulationMonoamine Oxidase InhibitorsParkinson DiseaseHumansMolecular StructureMonoamine OxidaseStructure-Activity RelationshipbenzimidazoleBenzimidazolesMonoamine OxidaseMonoamine Oxidase Inhibitorsbenzimidazoledockingdrug-likenessHuntington’s disease.MD simulationParkinson’s disease

Identifiers

PMID39449335
PMCPMC13223459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.